Reproducible Summary Tables with the gtsummary Package

Sjoberg, Daniel D.; Whiting, Karissa; Curry, Michael; Lavery, Jessica A.; Larmarange, Joseph

doi:10.32614/rj-2021-053

Cited by 416 publications

(208 citation statements)

References 4 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…Statistics were done using R 4.1.1 [26], the tidyverse [27], the gtsummary [28], the nnet [29], and the Ggally [30] packages.…”

Section: Participants and Methodsmentioning

confidence: 99%

See 1 more Smart Citation

When mistrust in the government and scientists reinforce social inequalities in vaccination against Covid-19

Bajos

Spire

Silberzan

et al. 2022

Preprint

View full text Add to dashboard Cite

Objective To assess whether mistrust in the government and scientists reinforces social and racial inequalities in vaccination practises Design A follow-up of a random population-based cohort survey. Setting In July 2021, in France. Participants 80,971 participants aged 18 years and more. Main outcome measures Adjusted odds ratios of Covid-19 vaccination status (received at least one dose/ intends to get vaccinated/ does not know whether to get vaccinated/refuses vaccination) were assessed using multinomial regressions to test associations with social and mistrust factors and to study how these two factors interacted with each other. Results In all, 72.2% were vaccinated at the time of the survey. The population of unvaccinated people was younger, less educated, had lower incomes, and more often belonged to racialised minorities, as compared to vaccinated people. Mistrust of government and scientists to curb the spread of the epidemic were the factors most associated with refusing to be vaccinated: OR=8.86 (7.13 to 11.00) for the government and OR=9.07 (7.71 to 10.07) for scientists, compared to vaccinated people. Mistrust was more prevalent among the poorer which consequently reinforced social inequalities in vaccination. The 10% poorest who did not trust the government reached an OR of 16.2 (11.9 to 22) for refusing to be vaccinated compared to the 10% richest who did. Conclusion There is a need to develop depoliticised outreach programmes targeted at the most socially disadvantaged groups, and to design vaccination strategies conceived with people from different social and racial backgrounds to enable them to make fully informed choices.

show abstract

“…Statistics were done using R 4.1.1 [26], the tidyverse [27], the gtsummary [28], the nnet [29], and the Ggally [30] packages.…”

Section: Participants and Methodsmentioning

confidence: 99%

“…Missing data was rare for all variables (<4%) and was deleted in multivariate analyses (n=7068, 8.7% excluded). Statistics were done using R 4.1.1 [26], the tidyverse [27], the gtsummary [28], the nnet [29], and the GGally [30] packages.…”

Section: Statistical Analysesmentioning

confidence: 99%

When mistrust in the government and scientists reinforce social inequalities in vaccination against Covid-19

Bajos

Spire

Silberzan

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…All descriptive analyses were performed using R (version 4.0.2; R Foundation for Statistical Computing). Tables were generated using the gtsummary package [ 19 ] and graphs were constructed using the ggplot2 package in R [ 20 ].…”

Section: Methodsmentioning

confidence: 99%

Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform

Brown¹,

Schleimer²,

Bledsoe³

et al. 2022

JMIR Hum Factors

View full text Add to dashboard Cite

Background People with Parkinson disease (PD) have a variety of complex medical problems that require detailed review at each clinical encounter for appropriate management. Care of other complex conditions has benefited from digital health solutions that efficiently integrate disparate clinical information. Although various digital approaches have been developed for research and care in PD, no digital solution to personalize and improve communication in a clinical encounter is readily available. Objective We intend to improve the efficacy and efficiency of clinical encounters with people with PD through the development of a platform (PD-BRIDGE) with personalized clinical information from the electronic health record (EHR) and patient-reported outcome (PRO) data. Methods Using human-centered design (HCD) processes, we engaged clinician and patient stakeholders in developing PD-BRIDGE through three phases: an inspiration phase involving focus groups and discussions with people having PD, an ideation phase generating preliminary mock-ups for feedback, and an implementation phase testing the platform. To qualitatively evaluate the platform, movement disorders neurologists and people with PD were sent questionnaires asking about the technical validity, usability, and clinical relevance of PD-BRIDGE after their encounter. Results The HCD process led to a platform with 4 modules. Among these, 3 modules that pulled data from the EHR include a longitudinal module showing motor ratings over time, a display module showing the most recently collected clinical rating scales, and another display module showing relevant laboratory values and diagnoses; the fourth module displays motor symptom fluctuation based on an at-home diary. In the implementation phase, PD-BRIDGE was used in 17 clinical encounters for patients cared for by 1 of 11 movement disorders neurologists. Most patients felt that PD-BRIDGE facilitated communication with their clinician (n=14, 83%) and helped them understand their disease trajectory (n=11, 65%) and their clinician’s recommendations (n=11, 65%). Neurologists felt that PD-BRIDGE improved their ability to understand the patients’ disease course (n=13, 75% of encounters), supported clinical care recommendations (n=15, 87%), and helped them communicate with their patients (n=14, 81%). In terms of improvements, neurologists noted that data in PD-BRIDGE were not exhaustive in 62% (n=11) of the encounters. Conclusions Integrating clinically relevant information from EHR and PRO data into a visually efficient platform (PD-BRIDGE) can facilitate clinical encounters with people with PD. Developing new modules with more disparate information could improve these complex encounters even further.

show abstract

“…All statistical analyses were performed using R version 4.1.1. The following R packages were used: survival (31), survminer, ggplot2 (32), pROC (33), gtsummary (34), swimplot, stats, rstatix.…”

Section: Methodsmentioning

confidence: 99%

Plasma cell-free DNA as a prognostic biomarker in small cell lung cancer patients

Mondelo‐Macía

García‐González

Abalo

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Lack of biomarkers for treatment selection and monitoring in small-cell lung cancer (SCLC) patients with the limited therapeutic options, result in poor outcomes. Therefore, new prognostic biomarkers are needed to improve their management. The prognostic value of cell-free DNA (cfDNA) and circulating tumor cells (CTCs) have been less explored in SCLC. Methods: We quantified cfDNA in 46 SCLC patients at different times during therapy. Moreover, CTCs were analyzed in 21 patients before therapy onset using CellSearch system. Both biomarkers were associated with patients outcomes and a prognostic model was developed. Results: High cfDNA levels before therapy were associated with shorter progression-free survival and overall survival. Furthermore, changes in cfDNA levels between baseline and 3 weeks and cfDNA levels at progression disease were also associated with patients outcomes. Multivariate analyses confirmed the independence of cfDNA levels as a prognostic biomarker. Finally, the three-risk category prognostic model developed included ECOG Performance Status, gender and baseline cfDNA levels was associated with a higher risk of progression and death. Conclusions: We confirmed the prognostic utility of cfDNA in SCLC patients before and during therapy. Our novel risk prognostic model in clinical practice will allow to identify patients who could benefit with actual therapies.

show abstract

Reproducible Summary Tables with the gtsummary Package

Cited by 416 publications

References 4 publications

When mistrust in the government and scientists reinforce social inequalities in vaccination against Covid-19

When mistrust in the government and scientists reinforce social inequalities in vaccination against Covid-19

Enhancing Clinical Information Display to Improve Patient Encounters: Human-Centered Design and Evaluation of the Parkinson Disease-BRIDGE Platform

Plasma cell-free DNA as a prognostic biomarker in small cell lung cancer patients

Contact Info

Product

Resources

About